These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 34190581)

  • 1. Immunotherapy for cholangiocarcinoma: a 2021 update.
    Charalampakis N; Papageorgiou G; Tsakatikas S; Fioretzaki R; Kole C; Kykalos S; Tolia M; Schizas D
    Immunotherapy; 2021 Sep; 13(13):1113-1134. PubMed ID: 34190581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biologics, Immunotherapy, and Future Directions in the Treatment of Advanced Cholangiocarcinoma.
    Saeed A; Park R; Al-Jumayli M; Al-Rajabi R; Sun W
    Clin Colorectal Cancer; 2019 Jun; 18(2):81-90. PubMed ID: 30905548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cholangiocarcinoma in the Era of Immunotherapy.
    Manthopoulou E; Ramai D; Dhar J; Samanta J; Ioannou A; Lusina E; Sacco R; Facciorusso A
    Vaccines (Basel); 2023 Jun; 11(6):. PubMed ID: 37376451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic Therapy for Primary Liver Tumors: Cholangiocarcinoma and Hepatocellular Carcinoma.
    Sadeghi S; Bejjani A; Finn RS
    Surg Oncol Clin N Am; 2019 Oct; 28(4):695-715. PubMed ID: 31472914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unveiling the promise of PD1/PD-L1: A new dawn in immunotherapy for cholangiocarcinoma.
    Chen F; Sheng J; Li X; Gao Z; Zhao S; Hu L; Chen M; Fei J; Song Z
    Biomed Pharmacother; 2024 Jun; 175():116659. PubMed ID: 38692063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic therapies for intrahepatic cholangiocarcinoma.
    Kelley RK; Bridgewater J; Gores GJ; Zhu AX
    J Hepatol; 2020 Feb; 72(2):353-363. PubMed ID: 31954497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells.
    Suriyo T; Fuangthong M; Artpradit C; Ungtrakul T; Sricharunrat T; Taha F; Satayavivad J
    Eur J Pharmacol; 2021 Apr; 897():173960. PubMed ID: 33617828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy of cholangiocarcinoma: Therapeutic strategies and predictive biomarkers.
    Chen R; Zheng D; Li Q; Xu S; Ye C; Jiang Q; Yan F; Jia Y; Zhang X; Ruan J
    Cancer Lett; 2022 Oct; 546():215853. PubMed ID: 35921970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune checkpoint inhibitors and combinations with other agents in cholangiocarcinoma.
    Skouteris N; Papageorgiou G; Fioretzaki R; Schizas D; Kykalos S; Tolia M; Charalampakis N
    Immunotherapy; 2023 May; 15(7):487-502. PubMed ID: 36876442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune suppressive checkpoint interactions in the tumour microenvironment of primary liver cancers.
    Zhou G; Boor PPC; Bruno MJ; Sprengers D; Kwekkeboom J
    Br J Cancer; 2022 Jan; 126(1):10-23. PubMed ID: 34400801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Desmoplastic Tumor Microenvironment and Immunotherapy in Cholangiocarcinoma.
    Høgdall D; Lewinska M; Andersen JB
    Trends Cancer; 2018 Mar; 4(3):239-255. PubMed ID: 29506673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overcoming Resistance to Immune Checkpoint Blockade in Liver Cancer with Combination Therapy: Stronger Together?
    Werner W; Kuzminskaya M; Lurje I; Tacke F; Hammerich L
    Semin Liver Dis; 2024 May; 44(2):159-179. PubMed ID: 38806159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune checkpoints and their promising prospect in cholangiocarcinoma treatment in combination with other therapeutic approaches.
    Vatankhah F; Salimi N; Khalaji A; Baradaran B
    Int Immunopharmacol; 2023 Jan; 114():109526. PubMed ID: 36481527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integration of radiotherapy with anti-PD-1 antibody for the treatment of intrahepatic or hilar cholangiocarcinoma: reflection from four cases.
    Zhao Q; Chen Y; Du S; Yang X; Chen Y; Ji Y; Zeng Z
    Cancer Biol Ther; 2021 Mar; 22(3):175-183. PubMed ID: 33722163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel and emerging targets for cholangiocarcinoma progression: therapeutic implications.
    Kankeu Fonkoua LA; Serrano Uson Junior PL; Mody K; Mahipal A; Borad MJ; Roberts LR
    Expert Opin Ther Targets; 2022 Jan; 26(1):79-92. PubMed ID: 35034558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of mTOR-inhibitors and mycophenolic acid on human cholangiocellular carcinoma and cancer associated fibroblasts.
    Heits N; Heinze T; Bernsmeier A; Kerber J; Hauser C; Becker T; Kalthoff H; Egberts JH; Braun F
    BMC Cancer; 2016 May; 16():322. PubMed ID: 27206490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted Therapies in Cholangiocarcinoma: Emerging Evidence from Clinical Trials.
    Simile MM; Bagella P; Vidili G; Spanu A; Manetti R; Seddaiu MA; Babudieri S; Madeddu G; Serra PA; Altana M; Paliogiannis P
    Medicina (Kaunas); 2019 Feb; 55(2):. PubMed ID: 30743998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Revisiting targeted therapy and immunotherapy for advanced cholangiocarcinoma.
    Du J; Lv X; Zhang Z; Huang Z; Zhang E
    Front Immunol; 2023; 14():1142690. PubMed ID: 36936931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of Immune Checkpoint Inhibitors in the Treatment of Cholangiocarcinoma.
    Zeng FL; Chen JF
    Technol Cancer Res Treat; 2021; 20():15330338211039952. PubMed ID: 34528830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogenic Vγ9Vδ2 T cell as new potential immunotherapy drug for solid tumor: a case study for cholangiocarcinoma.
    Alnaggar M; Xu Y; Li J; He J; Chen J; Li M; Wu Q; Lin L; Liang Y; Wang X; Li J; Hu Y; Chen Y; Xu K; Wu Y; Yin Z
    J Immunother Cancer; 2019 Feb; 7(1):36. PubMed ID: 30736852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.